Q4 EPS Forecast for Merit Medical Systems Lowered by Analyst

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Equities research analysts at Zacks Research dropped their Q4 2024 earnings per share (EPS) estimates for shares of Merit Medical Systems in a research note issued on Wednesday, November 20th. Zacks Research analyst I. Bandyopadhyay now expects that the medical instruments supplier will post earnings of $0.81 per share for the quarter, down from their prior estimate of $0.83. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.36 per share. Zacks Research also issued estimates for Merit Medical Systems’ Q3 2026 earnings at $1.07 EPS.

Merit Medical Systems (NASDAQ:MMSI) last announced its quarterly earnings results on Wednesday, October 30th. The medical instruments supplier reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.80 by $0.06. Merit Medical Systems had a return on equity of 15.61% and a net margin of 9.05%. The firm had revenue of $339.85 million for the quarter, compared to analysts’ expectations of $334.60 million. During the same period in the prior year, the business posted $0.75 earnings per share. The company’s revenue was up 7.8% on a year-over-year basis.

Several other brokerages also recently commented on MMSI. Robert W. Baird raised their price target on shares of Merit Medical Systems from $107.00 to $109.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. StockNews.com lowered Merit Medical Systems from a “buy” rating to a “hold” rating in a research note on Sunday, November 3rd. Needham & Company LLC restated a “buy” rating and issued a $109.00 target price on shares of Merit Medical Systems in a research note on Thursday, October 31st. Bank of America lifted their price target on Merit Medical Systems from $92.00 to $103.00 and gave the company a “neutral” rating in a research report on Monday, September 16th. Finally, Piper Sandler restated an “overweight” rating and issued a $110.00 price objective (up from $100.00) on shares of Merit Medical Systems in a research report on Monday, September 9th. Three investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Merit Medical Systems presently has a consensus rating of “Moderate Buy” and an average target price of $103.36.

Merit Medical Systems Price Performance

Shares of NASDAQ:MMSI opened at $105.33 on Monday. The company has a 50 day moving average of $98.59 and a 200 day moving average of $90.91. The company has a current ratio of 5.36, a quick ratio of 3.82 and a debt-to-equity ratio of 0.57. The stock has a market cap of $6.14 billion, a P/E ratio of 51.63, a P/E/G ratio of 2.61 and a beta of 0.89. Merit Medical Systems has a 12 month low of $65.46 and a 12 month high of $106.87.

Insider Buying and Selling

In related news, Director F. Ann Millner sold 12,500 shares of Merit Medical Systems stock in a transaction on Friday, November 15th. The shares were sold at an average price of $101.55, for a total value of $1,269,375.00. Following the transaction, the director now owns 32,391 shares in the company, valued at $3,289,306.05. This trade represents a 27.85 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Raul Jr. Parra sold 29,646 shares of the company’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $98.02, for a total transaction of $2,905,900.92. Following the sale, the chief financial officer now owns 16,361 shares of the company’s stock, valued at approximately $1,603,705.22. The trade was a 64.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Merit Medical Systems

Institutional investors and hedge funds have recently bought and sold shares of the stock. Opal Wealth Advisors LLC purchased a new stake in shares of Merit Medical Systems during the second quarter valued at approximately $29,000. DekaBank Deutsche Girozentrale purchased a new position in shares of Merit Medical Systems in the first quarter valued at about $44,000. USA Financial Formulas bought a new position in shares of Merit Medical Systems during the third quarter valued at about $59,000. GAMMA Investing LLC boosted its holdings in shares of Merit Medical Systems by 142.3% during the second quarter. GAMMA Investing LLC now owns 831 shares of the medical instruments supplier’s stock worth $71,000 after purchasing an additional 488 shares during the period. Finally, National Bank of Canada FI bought a new stake in shares of Merit Medical Systems in the second quarter worth about $77,000. 99.66% of the stock is currently owned by institutional investors.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.